About THINKER-NEXT
Transplanting Hepatitis C Kidneys Into Negative KidnEy Recipients
Kidney transplant extends life, improves quality of life, and reduces healthcare costs. Unfortunately, there are not enough donated kidneys, so many people who need a transplant spend years on the waiting list. Kidneys from organ donors who have hepatitis C virus (HCV) are often thrown away, but these kidneys work well, and hepatitis C can be cured. The goal of the THINKER-NEXT study is to make more kidneys available for transplant. THINKER-NEXT is a study that will provide HCV infected kidneys to people on the kidney transplant waiting list who do not have hepatitis C. We will then cure the HCV infection with an antiviral drug provided by Gilead free of charge
The National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) is funding this study to address key scientific questions related to transplants with respect to Hepatitis C.